Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies, a clinical-stage biopharmaceutical company, has appointed Tyler Martin as its new chief medical officer.
Subscribe to our email newsletter
Dr Martin will manage Dynavax’s clinical affairs, including the development of Dynavax’s three current clinical-stage product candidates and three preclinical candidates, which are expected to enter clinical development within 2010.
Most recently, Dr Martin was president of Humabs, and before that vice president of development at Chiron. He has also held senior development and research positions at Sangamo, Valentis, and SyStemix/GTI.
Dino Dina, president and CEO of Dynavax, said: “Tyler’s experience in infectious diseases and his demonstrated record of driving products through clinical development to support regulatory and commercial success will be instrumental as we advance our pipeline of products.”